CDTX - Cidara Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

24.15M

Cash

50.43M

Avg Qtr Burn

-276.3K

Short % of Float

1.72%

Insider Ownership

9.25%

Institutional Own.

33.74%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
REZZAYO (Rezafungin) Details Infectious disease, Fungal infections, Candidemia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rezafungin Details Infectious disease, Fungal infections	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CD388 (DFCs) Details Infectious disease, Influenza	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.